PDA-002 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Diabetic Nephropathies

Conditions

Diabetic Nephropathies, Peripheral Nervous System Diseases

Trial Timeline

Oct 27, 2015 → Oct 30, 2017

NCT ID

NCT02552277

About PDA-002 + Placebo

PDA-002 + Placebo is a phase 2 stage product being developed by Celularity for Diabetic Nephropathies. The current trial status is completed. This product is registered under clinical trial identifier NCT02552277. Target conditions include Diabetic Nephropathies, Peripheral Nervous System Diseases.

What happened to similar drugs?

20 of 20 similar drugs in Diabetic Nephropathies were approved

Approved (20) Terminated (3) Active (0)

✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved

✅Anplag(Sarpogrelate) + PlaceboYuhanApproved

✅Qutenza + PregabalinAstellas PharmaApproved

✅Duloxetine + Pregabalin + PlaceboShionogiApproved

✅duloxetine hydrochlorideEli LillyApproved

✅DuloxetineEli LillyApproved

✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02552277	Phase 2	Completed	Oct 27, 2015	Oct 30, 2017	Diabetic Nephropathies
NCT02460081	Phase 2	Withdrawn	Jun 1, 2015	Sep 1, 2017	Diabetic Foot

Competing Products

20 competing products in Diabetic Nephropathies

See all competitors

Product	Company	Stage	Hype Score
IVT aflibercept + Sham SC + SC CLS-TA	Clearside Biomedical	Phase 2	25
CHF6467 active	Comac Medical	Phase 1/2	22
Ruboxistaurin mesylate	Eli Lilly	Phase 3	40
KVD001 Injection	KalVista Pharmaceuticals	Phase 2	29
KVD001 Injection	KalVista Pharmaceuticals	Phase 1	23
Baricitinib + Placebo	Eli Lilly	Phase 2	35
LY3857210 + Placebo	Eli Lilly	Phase 2	35
UBX1325	Unity Biotechnology	Phase 2	25
Aflibercept + foselutoclax	Unity Biotechnology	Phase 2	25
UBX1325	Unity Biotechnology	Phase 1	19
CT-P42 + Eylea	Celltrion	Phase 3	40
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg	Yuhan	Approved	43
Anplag(Sarpogrelate) + Placebo	Yuhan	Approved	43
CS-3150 + placebo	Daiichi Sankyo	Phase 2	35
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule	Daiichi Sankyo	Phase 2	35
olmesartan medoxomil + Placebo Tablets	Daiichi Sankyo	Phase 3	40
DS-5565 + placebo	Daiichi Sankyo	Phase 3	40
Mirogabalin + Placebo	Daiichi Sankyo	Phase 3	40
DS-5565	Daiichi Sankyo	Phase 3	40
Beraprost sodium	Astellas Pharma	Pre-clinical	22